Genetic Key to Lupus Shows Potential of Personalized Medicine
By LabMedica International staff writers Posted on 02 Sep 2014 |
Image: The characteristic Malar rash or butterfly rash seen in a patient with systemic lupus erythematosus (Photo courtesy of the National Institute of Arthritis and Musculoskeletal and Skin Diseases).
DNA sequencing of a systemic lupus erythematosus (SLE) patient has identified a specific genetic mutation that is causing the disease, opening the way for personalized treatments.
The development shows that for the first time, it is feasible for scientists to identify the individual causes of SLE in patients by using DNA sequencing, allowing doctors to target specific treatments to individual patients.
A multidisciplinary team of scientists at the Australian National University (Canberra, Australia) performed whole exome sequencing in a four year old female with early-onset SLE and conducted biochemical analysis of the putative defect. Whole exome sequencing offers the possibility of identifying rare alleles responsible for disease in such cases as the genetic contribution to disease is most likely to be greatest in cases with early onset and severe phenotypes.
Whole exome sequencing of the female patient with cerebral lupus, who had suffered a stroke at the age of four, identified a rare, homozygous mutation in the Three Prime Repair Exonuclease 1 (TREX1) enzyme that was predicted to be highly deleterious. The TREX1 R97H mutant protein had a 20-fold reduction in exonuclease activity and was associated with an elevated Interferon alpha (IFN-α) signature in the patient. The discovery and characterization of a pathogenic TREX1 in the proband has therapeutic implications in that the patient is now a candidate for neutralizing anti-IFN-α therapy.
Carola G Vinues, LMS, PhD, a professor of in the department of Pathogens and Immunity and senior author of the study, said, “This is the new age of personalized medicine. This study shows that it is possible to unravel the detailed and individual genetic causes of lupus in individuals. Lupus is a heterogeneous disease and patients can experience a number of different symptoms. We believe that there are different genetic causes of lupus. Understanding these defective genes and pathways in each individual will help tailor treatments.” The patient's treating clinician, Jeffrey Chaitow, MBBCh, FRACP, said his young patient, now 10 years old, still needs regular steroids and immune suppressive drugs each day. The study was published online in August 2014 in the journal Arthritis & Rheumatology.
Related Links:
Australian National University
The development shows that for the first time, it is feasible for scientists to identify the individual causes of SLE in patients by using DNA sequencing, allowing doctors to target specific treatments to individual patients.
A multidisciplinary team of scientists at the Australian National University (Canberra, Australia) performed whole exome sequencing in a four year old female with early-onset SLE and conducted biochemical analysis of the putative defect. Whole exome sequencing offers the possibility of identifying rare alleles responsible for disease in such cases as the genetic contribution to disease is most likely to be greatest in cases with early onset and severe phenotypes.
Whole exome sequencing of the female patient with cerebral lupus, who had suffered a stroke at the age of four, identified a rare, homozygous mutation in the Three Prime Repair Exonuclease 1 (TREX1) enzyme that was predicted to be highly deleterious. The TREX1 R97H mutant protein had a 20-fold reduction in exonuclease activity and was associated with an elevated Interferon alpha (IFN-α) signature in the patient. The discovery and characterization of a pathogenic TREX1 in the proband has therapeutic implications in that the patient is now a candidate for neutralizing anti-IFN-α therapy.
Carola G Vinues, LMS, PhD, a professor of in the department of Pathogens and Immunity and senior author of the study, said, “This is the new age of personalized medicine. This study shows that it is possible to unravel the detailed and individual genetic causes of lupus in individuals. Lupus is a heterogeneous disease and patients can experience a number of different symptoms. We believe that there are different genetic causes of lupus. Understanding these defective genes and pathways in each individual will help tailor treatments.” The patient's treating clinician, Jeffrey Chaitow, MBBCh, FRACP, said his young patient, now 10 years old, still needs regular steroids and immune suppressive drugs each day. The study was published online in August 2014 in the journal Arthritis & Rheumatology.
Related Links:
Australian National University
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans